Skip to main content
Top

08-22-2018 | Hypoglycemia | Article

Male Patients with Longstanding Type 2 Diabetes Have a Higher Incidence of Hypoglycemia Compared with Female Patients

Journal: Diabetes Therapy

Authors: Feng-fei Li, Ying Zhang, Wen-li Zhang, Xiao-mei Liu, Mao-yuan Chen, Yi-xuan Sun, Xiao-fei Su, Jin-dan Wu, Lei Ye, Jian-hua Ma

Publisher: Springer Healthcare

Abstract

Introduction

To explore whether there was a gender difference in the risk of hypoglycemia during intensive insulin therapy in patients with longstanding type 2 diabetes (T2D). This was a post hoc analysis of a single-center, open-label and prospective trial.

Methods

All subjects were admitted as inpatients, underwent a standard bread meal test at baseline and received a 7-day continuous subcutaneous insulin infusion (CSII) therapy for achieving glycemic control. Patients then were randomized 1:1 to two groups receiving (1) 4 days of Novo Mix 30 followed by 2 days of Humalog Mix 50; (2) 4 days of Humalog Mix 50 followed by 2 days of Novo Mix 30. All patients were subjected to 4-day retrospective continuous glucose monitoring (CGM) during the last 4 days in this study. The primary outcome was the incidences of hypoglycemia monitored by CGM at the end point.

Results

A total of 102 patients met the inclusion criteria and completed the study. Our data revealed that 29 patients (28%) experienced hypoglycemia as detected by CGM at the end point. Binary logistic stepwise regression analysis showed that only gender significantly correlated with hypoglycemia (B = 1.17, p = 0.017). Importantly, male patients had a significantly higher incidence of hypoglycemia than female patients (male = 20/52, female = 9/50, p = 0.022), although male patients required significantly lower insulin doses to maintain glycemic control than female patient (p = 0.00).

Conclusion

Male patients with longstanding T2D had a higher incidence of hypoglycemia than female patients during intensive insulin therapy.

Trial registration

ClinicalTrials.gov identifier, ChiCTR-IPR-15007340.
Literature
1.
Esteghamati A, Mousavizadeh M, Noshad S, et al. Gender-dependent effects of metformin on vaspin and adiponectin in type 2 diabetes patients: a randomized clinical trial. Hormone Metab Res. 2013;45(4):319–25.
2.
Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev. 2016;37(3):278–316.CrossRefPubMedPubMedCentral
3.
Glechner A, Harreiter J, Gartlehner G, et al. Sex-specific differences in diabetes prevention: a systematic review and meta-analysis. Diabetologia. 2015;58(2):242–54.CrossRefPubMed
4.
Li FF, Liu BL, Zhu HH, et al. Continuous glucose monitoring in newly diagnosed type 2 diabetes patients reveals a potential risk of hypoglycemia in older men. J Diabetes Res. 2017;2740372.
5.
Harreiter J, Kautzky-Willer A. Sex and gender differences in prevention of type 2 diabetes. Front Endocrinol. 2018;9:220.CrossRef
6.
Li FF, Fu LY, Zhang WL, et al. Blood glucose fluctuations in type 2 diabetes patients treated with multiple daily injections. J Diabetes Res 2016;1028945.
7.
Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371(9626):1753–60.CrossRefPubMed
8.
Retnakaran R, Drucker DJ. Intensive insulin therapy in newly diagnosed type 2 diabetes. Lancet. 2008;371(9626):1725–6.CrossRefPubMed
9.
Ilkova H, Glaser B, Tunckale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care. 1997;20(9):1353–6.CrossRefPubMed
10.
Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004;27(11):2597–602.CrossRefPubMed
11.
Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004;27(5):1028–32.CrossRefPubMed
12.
Reznik Y, Cohen O, Aronson R, et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet. 2014;384(9950):1265–72.CrossRefPubMed
13.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.CrossRef
14.
Lv WS, Li L, Wen JP, et al. Comparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short-term intensive insulin therapy for poorly controlled type 2 diabetes patients. Int J Endocrinol. 2013; 614242.
15.
The DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med. 1991;90(4):450–9.CrossRef
16.
Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28(7):1568–73.CrossRefPubMed
17.
Bremer JP, Jauch-Chara K, Hallschmid M, et al. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32(8):1513–7.CrossRefPubMedPubMedCentral
18.
Li FF, Liu BL, Yin GP, et al. Young onset type 2 diabetic patients might be more sensitive to metformin compared to late onset type 2 diabetic patients. Sci Rep. 2017;7(1):16382.CrossRefPubMedPubMedCentral
19.
Li H, Li W, Gu Y, et al. Comparison of continual insulin or secretagogue treatment in type 2 diabetic patients with alternate insulin-secretagogue administration. Diabetes Res Clin Pract. 2009;84(2):158–62.CrossRefPubMed
20.
Li FF, Zhang WL, Liu BL, et al. Management of glycemic variation in diabetic patients receiving parenteral nutrition by continuous subcutaneous insulin infusion (CSII) therapy. Sci Rep. 2018;8(1):5888.CrossRefPubMedPubMedCentral
21.
Li FF, Jiang L, Fu L, et al. Exenatide add-on to continuous subcutaneous insulin infusion therapy reduces bolus insulin doses in patients with type 2 diabetes: a randomized, controlled, open-label trial. Diabetes Ther. 2017;8(1):177–87.CrossRefPubMed
22.
Li FF, Xu XH, Fu LY, et al. Influence of acarbose on plasma glucose fluctuations in insulin-treated patients with type 2 diabetes: a pilot study. Int J Endocrinol. 2015;903524.
23.
Li FF, Shen Y, Sun R, et al. Effects of Vildagliptin add-on insulin therapy on nocturnal glycemic variations in uncontrolled type 2 diabetes. Diabetes Ther. 2017;8(5):1111–22.CrossRefPubMedPubMedCentral
24.
Li FF, Liu BL, Yan RN, et al. Features of glycemic variations in drug naive type 2 diabetic patients with different HbA1c values. Sci Rep. 2017;7(1):1583.CrossRefPubMedPubMedCentral
25.
Haahr H, Sasaki T, Bardtrum L, et al. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects. J Diabetes Investig. 2016;7(4):574–80.CrossRefPubMedPubMedCentral
26.
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.CrossRefPubMed
27.
Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–70.CrossRefPubMed
28.
Sasaki R, Yano Y, Yasuma T, et al. Association of waist circumference and body fat weight with insulin resistance in male subjects with normal body mass index and normal glucose tolerance. Intern Med. 2016;55(11):1425–32.CrossRefPubMed
29.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.CrossRefPubMed
30.
Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473–8.CrossRefPubMedPubMedCentral
31.
Del Prato S. In search of normoglycaemia in diabetes: controlling postprandial glucose. Int J Obes Relat Metab Disord. 2002;26(Suppl 3):S9–17.CrossRefPubMed
32.
Jia W, Xiao X, Ji Q, et al. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial. Lancet Diabetes Endocrinol. 2015;3(4):254–62.CrossRefPubMed
33.
Retnakaran R, Yakubovich N, Qi Y, et al. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab. 2010;12(1):65–71.CrossRefPubMed
34.
Reznik Y, Cohen O, Aronson R, et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet. 2014;384(9950):1265–72.CrossRefPubMed
35.
Yeoh E, Beato-Vibora P, Rogers H, et al. Efficacy of insulin pump therapy in elderly patients. Diabetes Technol Ther. 2015;17(5):364–5.CrossRefPubMed
36.
Ntuk UE, Gill JM, Mackay DF, et al. Ethnic-specific obesity cutoffs for diabetes risk: cross-sectional study of 490,288 UK biobank participants. Diabetes Care. 2014;37(9):2500–7.CrossRefPubMed

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »